NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · IEX Real-Time Price · USD
18.90
+0.14 (0.75%)
At close: Jul 19, 2024, 4:00 PM
18.96
+0.06 (0.32%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
NAMS Employees
NewAmsterdam Pharma Company had 29 employees as of December 31, 2023. The number of employees increased by 12 or 70.59% compared to the previous year.
Employees
29
Change
12
Growth
70.59%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
1.70B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 29 | 12 | 70.59% |
Nov 22, 2022 | 17 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Evotec SE | 4,952 |
Galapagos NV | 1,123 |
Schrödinger | 867 |
Veracyte | 815 |
Supernus Pharmaceuticals | 652 |
Avadel Pharmaceuticals | 154 |
Kura Oncology | 142 |
Keros Therapeutics | 136 |
NAMS News
- 14 days ago - NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors - GlobeNewsWire
- 18 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease - GlobeNewsWire
- 3 months ago - BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors - Business Wire
- 4 months ago - NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer - GlobeNewsWire
- 4 months ago - NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress - GlobeNewsWire
- 4 months ago - NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD - GlobeNewsWire